




Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





NeoLAB® Solid Tumor Liquid Biopsy

Methodology

Molecular

Test Description

The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%.

- SNVs and indels (969 mutations across these 44 genes): AKT1, ALK, APC, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SF3B1, SMAD4, SMO, and TP53.

NOTE: Not available for samples from New York.

Clinical Significance

Liquid biopsy (also called plasma testing) is appropriate for situations when tissue is insufficient, unavailable, or not practical to obtain, or when results are needed more quickly than they can be obtained from tissue analysis. The NeoLAB® Solid Tumor Liquid Biopsy includes targets significant to a wide variety of solid tumors including colorectal, pancreas, prostate, melanoma, head & neck, bladder, thyroid, kidney, ovarian, liver, thyroid, breast, and lung*. Tissue testing is recommended over plasma testing when possible.

*See also our other liquid biopsy [InVisionFirst®-Lung](#) for lung.

Specimen Requirements

- **Peripheral blood:** two x 10 mL Streck Cell-Free DNA BCT® tubes

Storage & Transportation

Do not refrigerate. Request collection kits from Client Services and see collection and shipping instructions [here](#) (also included in kit).

CPT Code(s)*

81445

New York Approved

No

Level of Service

Global

Turnaround Time

7 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2023 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 032223